Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04417621 | Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | PHASE2 | ACTIVE NOT_RECRUITING | 134 | — | — | Oct 30, 2020 | Feb 2, 2027 | Mar 12, 2026 | 36 | United States, Argentina +10 |
Confirmed ORR using RECIST v1.1, per local assessment
| Arm | Type | Description |
|---|---|---|
| LXH254 + LTT462 | EXPERIMENTAL | - |
| LXH254 + trametinib | EXPERIMENTAL | - |
| LXH254 + ribociclib | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LXH254 | DRUG | LXH254 will be supplied as tablet for oral use. |
| LTT462 | DRUG | LTT462 will be supplied as hard gelatin capsule for oral use. |
| Trametinib | DRUG | Trametinib will be supplied as film-coated tablet for oral use |
| Ribociclib | DRUG | Ribociclib will be supplied in tablets and hard gelatin capsules. |
Inclusion Criteria: Male or female must be ≥ 12 years For adolescents only (12-17 years): body weight \> 40kg Histologically confirmed unresectable or metastatic cutaneous melanoma Previously treated for unresectable or metastatic melanoma: * Participants with NRAS mutation: * Participants must h...